Affiliation:
1. Cardiovascular-Genetic Center, IRCCS Policlinico San Donato, 20097 Milan, Italy
2. Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, 20097 Milan, Italy
3. Department of Biosciences, University of Milan, 20122 Milan, Italy
Abstract
Marfan syndrome (MFS) is a rare congenital disorder of the connective tissue, leading to thoracic aortic aneurysms (TAA) and dissection, among other complications. Currently, the most efficient strategy to prevent life-threatening dissection is preventive surgery. Periodic imaging applying complex techniques is required to monitor TAA progression and to guide the timing of surgical intervention. Thus, there is an acute demand for non-invasive biomarkers for diagnosis and prognosis, as well as for innovative therapeutic targets of MFS. Unraveling the intricate pathomolecular mechanisms underlying the syndrome is vital to address these needs. High-throughput platforms are particularly well-suited for this purpose, as they enable the integration of different datasets, such as transcriptomic and epigenetic profiles. In this narrative review, we summarize relevant studies investigating changes in both the coding and non-coding transcriptome and epigenome in MFS-induced TAA. The collective findings highlight the implicated pathways, such as TGF-β signaling, extracellular matrix structure, inflammation, and mitochondrial dysfunction. Potential candidates as biomarkers, such as miR-200c, as well as therapeutic targets emerged, like Tfam, associated with mitochondrial respiration, or miR-632, stimulating endothelial-to-mesenchymal transition. While these discoveries are promising, rigorous and extensive validation in large patient cohorts is indispensable to confirm their clinical relevance and therapeutic potential.
Funder
Italian Ministry of Health projects Ricerca Corrente
Italian Ministry of Health projects Ricerca Finalizzata
POS T4 CAL.HUB.RIA
Next Generation EU-NRRP M6C2 Inv. 2.1
Next Generation EU PNRR
Telethon Foundation
AFM-Telethon grant